IL316673A - Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE - Google Patents

Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE

Info

Publication number
IL316673A
IL316673A IL316673A IL31667324A IL316673A IL 316673 A IL316673 A IL 316673A IL 316673 A IL316673 A IL 316673A IL 31667324 A IL31667324 A IL 31667324A IL 316673 A IL316673 A IL 316673A
Authority
IL
Israel
Prior art keywords
antibody
fxi
fxia
seq
amino acid
Prior art date
Application number
IL316673A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL316673A publication Critical patent/IL316673A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL316673A 2016-12-23 2017-12-22 Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE IL316673A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438654P 2016-12-23 2016-12-23
US201762589851P 2017-11-22 2017-11-22
PCT/IB2017/058345 WO2018116267A2 (en) 2016-12-23 2017-12-22 Methods of treatment with anti-factor xi/xia antibodies

Publications (1)

Publication Number Publication Date
IL316673A true IL316673A (en) 2024-12-01

Family

ID=61022382

Family Applications (2)

Application Number Title Priority Date Filing Date
IL316673A IL316673A (en) 2016-12-23 2017-12-22 Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE
IL267519A IL267519B2 (en) 2016-12-23 2017-12-22 Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL267519A IL267519B2 (en) 2016-12-23 2017-12-22 Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease

Country Status (9)

Country Link
US (3) US20200231701A1 (enExample)
EP (1) EP3558370A2 (enExample)
JP (3) JP7110199B2 (enExample)
KR (2) KR102702288B1 (enExample)
CN (2) CN118320078A (enExample)
AU (2) AU2017383537B2 (enExample)
CA (1) CA3048157A1 (enExample)
IL (2) IL316673A (enExample)
WO (1) WO2018116267A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6799530B2 (ja) 2014-10-01 2020-12-16 メディミューン リミテッド チカグレロルに対する抗体および使用方法
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3558370A2 (en) * 2016-12-23 2019-10-30 Novartis AG Methods of treatment with anti-factor xi/xia antibodies
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
DK3852617T3 (da) 2018-09-20 2025-10-20 Sfj Pharma X Inc Anvendelse af antistof fragmenter til revertering af ticagrelor-aktivitet
WO2020211674A1 (zh) 2019-04-16 2020-10-22 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
BR112022012064A2 (pt) * 2019-12-20 2022-08-30 Anthos Therapeutics Inc Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
KR100246529B1 (ko) 1990-12-14 2000-04-01 스티븐 에이. 서윈. 엠.디. 수용체 관련된 신호 변환 경로를 위한 키메라 사슬
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
JP4638035B2 (ja) * 1998-08-28 2011-02-23 ジェネンテック， インコーポレイテッド ヒト抗−ＩＸ／ＩＸａ因子抗体
EP1278767A4 (en) 2000-04-12 2003-11-12 Principia Pharmaceutical Corp ALBUMIN FUSED PROTEINS
NZ522632A (en) * 2000-05-15 2005-05-27 Smithkline Beecham Corp Antithrombotic agents
WO2009067660A2 (en) * 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
EP2297207B1 (en) * 2008-06-19 2018-10-03 Prothix BV Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
ES2720594T3 (es) * 2008-12-18 2019-07-23 Univ Oregon Health & Science Anticuerpos anti-fXI y métodos de uso
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
WO2013167669A1 (en) * 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3558370A2 (en) * 2016-12-23 2019-10-30 Novartis AG Methods of treatment with anti-factor xi/xia antibodies

Also Published As

Publication number Publication date
JP7500662B2 (ja) 2024-06-17
AU2017383537B2 (en) 2024-10-03
KR20240134248A (ko) 2024-09-06
JP2024116221A (ja) 2024-08-27
IL267519B1 (en) 2024-12-01
JP2020504110A (ja) 2020-02-06
EP3558370A2 (en) 2019-10-30
US20200231701A1 (en) 2020-07-23
KR20190099256A (ko) 2019-08-26
US20230002507A1 (en) 2023-01-05
IL267519B2 (en) 2025-04-01
WO2018116267A2 (en) 2018-06-28
KR102702288B1 (ko) 2024-09-05
CN110325211A (zh) 2019-10-11
JP7110199B2 (ja) 2022-08-01
AU2024287181A1 (en) 2025-03-06
AU2017383537A1 (en) 2019-06-27
WO2018116267A3 (en) 2018-08-02
CA3048157A1 (en) 2018-06-28
IL267519A (en) 2019-08-29
CN118320078A (zh) 2024-07-12
US20250197522A1 (en) 2025-06-19
JP2022141831A (ja) 2022-09-29

Similar Documents

Publication Publication Date Title
US20240067750A1 (en) Factor xi antibodies and methods of use
US20250197522A1 (en) Methods of treatment with anti-factor xi/xia antibodies
US12012464B2 (en) Factor XI antibodies and methods of use